Bellerophon Therapeutics, Inc. BLPH
We take great care to ensure that the data presented and summarized in this overview for Bellerophon Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding BLPH
View allLatest Institutional Activity in BLPH
Top Purchases
Top Sells
About BLPH
Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its product includes INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse that is in Phase 3 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; which has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that has completed Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension and pulmonary hypertension associated with pulmonary edema from high altitude sickness. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.
Insider Transactions at BLPH
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 13
2023
|
Puissance Capital Management LP > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
1,076,841
-100.0%
|
$0
$0.1 P/Share
|
|
Jun 07
2023
|
Naseem Amin Director |
BUY
Grant, award, or other acquisition
|
Direct |
47,578
+14.02%
|
-
|
|
Jun 07
2023
|
Puissance Life Science Opportunities Fund Vi > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
134,421
-11.1%
|
$0
$0.83 P/Share
|
|
May 18
2023
|
Bobae Kim VP Reg. Affairs & Quality |
SELL
Open market or private sale
|
Direct |
9,455
-84.59%
|
$94,550
$10.0 P/Share
|
|
May 18
2023
|
Bobae Kim VP Reg. Affairs & Quality |
BUY
Exercise of conversion of derivative security
|
Direct |
1,288
+25.3%
|
$9,016
$7.43 P/Share
|
|
May 18
2023
|
Puissance Life Science Opportunities Fund Vi > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
560,000
-31.62%
|
$5,040,000
$9.46 P/Share
|
|
Feb 10
2023
|
Naseem Amin Director |
BUY
Grant, award, or other acquisition
|
Direct |
84,000
+25.59%
|
-
|
|
Dec 09
2022
|
Peter Fernandes Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
9,985
-30.72%
|
$0
$0.93 P/Share
|
|
Dec 09
2022
|
Peter Fernandes Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
32,500
+50.0%
|
-
|
|
Dec 09
2022
|
Nicholas Laccona FINANCIAL OFFICER, (PFO & PAO) |
SELL
Payment of exercise price or tax liability
|
Direct |
5,530
-30.72%
|
$0
$0.93 P/Share
|
|
Dec 09
2022
|
Nicholas Laccona FINANCIAL OFFICER, (PFO & PAO) |
BUY
Exercise of conversion of derivative security
|
Direct |
18,000
+50.0%
|
-
|
|
Dec 09
2022
|
Parag Suresh Shah VP of Business Operations |
SELL
Payment of exercise price or tax liability
|
Direct |
7,834
-30.72%
|
$0
$0.93 P/Share
|
|
Dec 09
2022
|
Parag Suresh Shah VP of Business Operations |
BUY
Exercise of conversion of derivative security
|
Direct |
25,500
+50.0%
|
-
|
|
Dec 09
2022
|
Martin Dekker Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
7,834
-30.72%
|
$0
$0.93 P/Share
|
|
Dec 09
2022
|
Martin Dekker Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
25,500
+50.0%
|
-
|
|
Dec 31
2021
|
Naseem Amin Director |
BUY
Grant, award, or other acquisition
|
Direct |
39,032
+19.58%
|
-
|
|
Jun 07
2021
|
Puissance Life Science Opportunities Fund Vi > 10% Shareholder |
BUY
Grant, award, or other acquisition
|
Direct |
8,189
+0.46%
|
$32,756
$4.0 P/Share
|
|
Apr 26
2021
|
Puissance Life Science Opportunities Fund Vi > 10% Shareholder |
BUY
Grant, award, or other acquisition
|
Direct |
609,231
+25.68%
|
$2,436,924
$4.0 P/Share
|
|
Mar 31
2021
|
Jonathan M Peacock |
BUY
Grant, award, or other acquisition
|
Direct |
15,308
+8.88%
|
-
|
|
Mar 18
2021
|
New Mountain Investments Ii, LLC |
SELL
Open market or private sale
|
Direct |
400,000
-39.63%
|
$2,000,000
$5.48 P/Share
|